Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals is a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver broad clinical utility across multiple therapeutic areas. Arena's proprietary pipeline includes potentially first- or best-in-class programs for which they own global commercial rights. Arena's APD371, a CB2 agonist, is in clinical-stage studies. The CB2 receptor is part of the naturally occurring cannabinoid receptor system in our bodies.